Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation...

Area of Science:

• Molecular biology
• Cancer research
• Drug discovery

Background:

• Hec1 (highly expressed in cancer 1) and Nek2 (NIMA-related kinase 2) are overexpressed in aggressive cancers.
• Both proteins are crucial for cell division and chromosome segregation.
• Targeting their interaction is a potential cancer therapy strategy.

Purpose of the Study:

• To develop and characterize novel small molecule inhibitors targeting the Hec1-Nek2 interaction.
• To elucidate the mechanism of action of these inhibitors.
• To evaluate the therapeutic potential of these inhibitors in preclinical models.

Main Methods:

• Synthesis and characterization of novel INH (inhibitor for Nek2 and Hec1 binding) derivatives.
• Biochemical assays to determine binding sites and inhibition of Hec1 phosphorylation.
• Cell-based assays to assess cancer cell killing and protein degradation.
• In vivo studies in mouse tumor models.

Main Results:

• New INH derivatives bind to Hec1 at amino acids 394-408, blocking Nek2 phosphorylation of Hec1 S165.
• These inhibitors kill cancer cells at nanomolar concentrations.
• INH binding to Hec1 triggers proteasome-mediated degradation of Nek2.
• Co-expression of Hec1 and Nek2 correlates with poor survival in breast cancer patients.
• INH treatment suppressed tumor growth in mice with minimal toxicity.

Conclusions:

• Novel INH derivatives represent a new class of anti-cancer agents targeting Hec1-Nek2 interaction.
• The mechanism involves a "virtual death-trap" leading to Nek2 degradation and cancer cell death.
• These findings support the clinical translation of INH derivatives for treating Hec1 and Nek2-overexpressing cancers.